These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing, reported early 2004-000443-17 A Randomized, Double-Blind Trial of Telbivudine (LdT) versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis not-yet-due
Listed as ongoing, but also has a completion date and reported results 2004-003754-26 A Randomized, Double-Blind Trial of Telbivudine (LdT) versus Continued Lamivudine Treatment in Adults with Compensated Chronic Hepatitis B Who are Currently Receiving Lamivudine Treatment 2006-08-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-004274-87 An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies 2010-05-27 bad-data
Exempt, with results 2008-005558-19 A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Antiviral Activity of IDX184 in Treatment-Naïve Subjects Infected with Genotype 1 Chronic Hepatitis C 2010-01-10 not-yet-due
Exempt, with results 2009-018079-15 A Phase I/IIa Study Assessing Single and Multiple Doses of HCV Protease Inhibitor IDX320 in Healthy and Genotype 1 HCV-Infected Subjects 2010-08-30 not-yet-due
Reported results 2011-001878-25 A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination with Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects with Genotype 1... 2014-10-31 due-trials
Reported results Terminated 2012-005636-29 3-Year, Observational Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting... 2015-03-20 due-trials
Exempt, with results 2013-004043-23 A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects not-yet-due